What's Happening?
Institut Pasteur has initiated ACT-CHIK, a four-year research project aimed at advancing the development of a chikungunya vaccine in Africa. Funded by the European Union's Horizon Europe program, the project will conduct large-scale clinical trials in four African
countries and prepare for technology transfer to an African vaccine manufacturer. Chikungunya, a mosquito-borne viral disease, has seen a rise in cases across Africa, exacerbated by climate change. The project seeks to address the underdiagnosis and under-reporting of the disease and improve vaccine accessibility in endemic regions.
Why It's Important?
The ACT-CHIK project is significant as it addresses a neglected disease that poses a growing health burden in Africa. By advancing vaccine development and manufacturing capabilities on the continent, the initiative aims to improve equitable access to vaccination and strengthen outbreak preparedness. The project aligns with Africa's goal to produce 60% of its vaccine needs locally by 2040, supporting regional health security and reducing dependency on external vaccine supplies.
What's Next?
The project will conduct a Phase Ib/III clinical trial to evaluate the safety and immunogenicity of the MV-CHIK vaccine in various age groups across Rwanda, Kenya, Nigeria, and Senegal. It will also prepare for the technology transfer of vaccine manufacturing to the Institut Pasteur de Dakar. Engagement with national regulatory authorities and the World Health Organization will be crucial for obtaining vaccine licensure and prequalification in Africa.
